{"title":"影响慢性荨麻疹患者奥玛单抗治疗后复发的因素。停药的方法会影响复发吗?","authors":"Petek Üstün, Esra Adışen","doi":"10.5826/dpc.1503a5196","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Omalizumab is recommended for chronic urticaria (CU) until spontaneous remission occurs rather than for a specific period of time. The rate of relapse after treatment varies depending on the method of discontinuation.</p><p><strong>Objectives: </strong>Our study aimed to investigate how the method of omalizumab discontinuation and other factors affect the rate of post-treatment relapses.</p><p><strong>Methods: </strong>Patients with CU were divided into three groups based on their method of discontinuing omalizumab treatment: direct discontinuation, extending treatment intervals to eight weeks, and reducing the treatment dose to 150 mg/4 weeks. These groups were then compared for relapse rates.</p><p><strong>Results: </strong>A total of 200 patients were included in this study. Among the 109 patients who discontinued omalizumab directly, 65.1% experienced a relapse. The relapse rate was 40.7% in those who extended the treatment intervals to eight weeks and 15.6% in those who reduced the dose to 150 mg/4 weeks. There was a statistically significant difference in post-treatment relapse rates according to the method of discontinuation (P< 0.001).</p><p><strong>Conclusions: </strong>Gradual tapering of treatment rather than direct discontinuation has been shown to prolong remission. Achieving the lowest relapse rate with a reduction in the treatment dose to 150 mg/4 weeks is significant for the design of omalizumab discontinuation protocol and provides insights for future studies.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"15 3","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339098/pdf/","citationCount":"0","resultStr":"{\"title\":\"Factors Influencing Relapse After Omalizumab in Chronic Urticaria. Does the Method of Discontinuation Influence Relapse?\",\"authors\":\"Petek Üstün, Esra Adışen\",\"doi\":\"10.5826/dpc.1503a5196\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Omalizumab is recommended for chronic urticaria (CU) until spontaneous remission occurs rather than for a specific period of time. The rate of relapse after treatment varies depending on the method of discontinuation.</p><p><strong>Objectives: </strong>Our study aimed to investigate how the method of omalizumab discontinuation and other factors affect the rate of post-treatment relapses.</p><p><strong>Methods: </strong>Patients with CU were divided into three groups based on their method of discontinuing omalizumab treatment: direct discontinuation, extending treatment intervals to eight weeks, and reducing the treatment dose to 150 mg/4 weeks. These groups were then compared for relapse rates.</p><p><strong>Results: </strong>A total of 200 patients were included in this study. Among the 109 patients who discontinued omalizumab directly, 65.1% experienced a relapse. The relapse rate was 40.7% in those who extended the treatment intervals to eight weeks and 15.6% in those who reduced the dose to 150 mg/4 weeks. There was a statistically significant difference in post-treatment relapse rates according to the method of discontinuation (P< 0.001).</p><p><strong>Conclusions: </strong>Gradual tapering of treatment rather than direct discontinuation has been shown to prolong remission. Achieving the lowest relapse rate with a reduction in the treatment dose to 150 mg/4 weeks is significant for the design of omalizumab discontinuation protocol and provides insights for future studies.</p>\",\"PeriodicalId\":11168,\"journal\":{\"name\":\"Dermatology practical & conceptual\",\"volume\":\"15 3\",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339098/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology practical & conceptual\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5826/dpc.1503a5196\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology practical & conceptual","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5826/dpc.1503a5196","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Factors Influencing Relapse After Omalizumab in Chronic Urticaria. Does the Method of Discontinuation Influence Relapse?
Introduction: Omalizumab is recommended for chronic urticaria (CU) until spontaneous remission occurs rather than for a specific period of time. The rate of relapse after treatment varies depending on the method of discontinuation.
Objectives: Our study aimed to investigate how the method of omalizumab discontinuation and other factors affect the rate of post-treatment relapses.
Methods: Patients with CU were divided into three groups based on their method of discontinuing omalizumab treatment: direct discontinuation, extending treatment intervals to eight weeks, and reducing the treatment dose to 150 mg/4 weeks. These groups were then compared for relapse rates.
Results: A total of 200 patients were included in this study. Among the 109 patients who discontinued omalizumab directly, 65.1% experienced a relapse. The relapse rate was 40.7% in those who extended the treatment intervals to eight weeks and 15.6% in those who reduced the dose to 150 mg/4 weeks. There was a statistically significant difference in post-treatment relapse rates according to the method of discontinuation (P< 0.001).
Conclusions: Gradual tapering of treatment rather than direct discontinuation has been shown to prolong remission. Achieving the lowest relapse rate with a reduction in the treatment dose to 150 mg/4 weeks is significant for the design of omalizumab discontinuation protocol and provides insights for future studies.